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Coeliac disease (CD), also known as coeliac sprue, non-tropical sprue, and 
gluten-sensitive enteropathy, is an inflammatory disease of the upper small intestine 
that results from gluten ingestion in genetically susceptible individuals1. 
The characteristic mucosal inflammation, villous atrophy 
and crypt hyperplasia that occur upon exposure to gluten 
leads to malabsorption of several important nutrients. 
CD was first formally described in 1888, by Samuel Gee 
in the St Bartholomew's Hospital reports 2• The central 
role of gluten in the pathogenesis of CD was observed 
by Dicke in 19503• He noted that persons previously 
diagnosed with CD improved during World War II when 
grain products were in short supply whilst when grains 
became more plentiful after the war, the incidence of 
coeliac disease returned to its pre-war levels. CD is 
associated with dermatitis herpetiformis4 a typical skin 
rash that similarly to CD responds to withdrawal of 
gluten. Untreated CD is associated with multiple, short 
and long-term complications including nutritional 
derangements, anaemia, reduced bone density, as well 
as intestinal lymphoma. 
Though its triggering factor (surgery, pregnancy, 
childbirth, viral infections and stress have all been 
implicated at some time or other) and its polygenic 
basis is still mostly unknown, CD is unique amongst 
the inflammatory diseases in that the causative agent 
is known, i.e. gluten. This fact projects CD as a possible 
model for the study of inflammatory disease. 
In the 1980's, Marsh demonstrated that the immune 
system played an important role in causing intestinal injury 
in coeliac diseases. It has been shown that CD is the result 
of the activation of both a cell-mediated (T-cell) and 
humoral (B -cell) immune response upon exposure to the 
glutens (prolamins and glutenins) of wheat, barley, rye, 
and oats, in a genetically susceptible person6. 
CD was thought to be uncommon but in the last two 
decades, it has been realised that the condition is relatively 
common, affecting 1 in every 100 persons7-9 to 1 in 50 
persons 10. Traditionally CD was regarded as a childhood 
disease but it is now clear that CD can occur at any age, 
with the fifth decade being the peak incidence in adults. 
Females are more commonly affected than males with a 
female to male ratio of around 3 to 1. The increased 
incidence ofthe condition can be partly explained through 
the greater awareness of Its presentatIOn and the 
availability of accurate serologic tests, though an actual 
increase as a result of as yet unknown triggering factors 
cannot be ruled out. The serologIcal tests that helped to 
put CD in the forefront are the anti-gliadin antibodies 
(lgA and IgG), anti-endomyseal antibodies and recently 
the identification of anti-Transglutaminase antibody. The 
latter test has a very high sensitivity and specificity (99% 
and 98% respectively) making it ideal as an initial 
screening test. 
Genetic predisposition, as indicated by the high 
concordance between monozygotic twins and the high 
prevalence amongst family members of affected 
individuals, plays a major role in CD. In the last decade 
or so considerable progress has been made in identifying 
genes that are responsible for CD predisposition. HLA 
Class 11 genes have been positively identified as a 
predisposing genetic factor for CD. The condition is 
strongly associated with the specific HLA class 11 genes 
known as HLA-DQ2 and HLA-DQ8 located on 
chromosome 6p21. HLA-DQ2 is found in the majority 
of CD patients (95%) whilst the remaining are usually 
HLA-DQ8 positive. As the HLA-DQ2 allele is very 
common in the population (around 30% of Caucasian 
individuals), it was clear that though the HLA type 
background is necessary for CD, it is not sufficient for 
CD to develop. The HLA locus has been assigned as 
the CELlA Cl locus. HLA testing, specifically for the 
DQ2 and DQ8 alleles, is useful as an exclusive test, i.e. 
those individuals that are negative for the DQ2 and 
DQ8 are very unlikely to have CD. 
Non-HLA genes have a higher genetic contribution 
towards CD compared to HLA genes; however, the 
predisposition depends on a number of genes, each of 
which adds a minor contribution to disease development. 
This small effect size compounded with genetic 
heterogeneity between populations, has made non-HLA 
coeliac disease predisposing genes very difficult to 
identify and reproduce. 
The CELlAC2 locus has been identified on chromosome 
5, delimited by the genetic markers D5S41O and D5S402 
within region 5q31-q33. This marker has been confirmed 
as a disease locus for CD in the recent European Cluster 
study on CDII. Though a number of inflammatory related 
genes exist in this area, the positive identification of the 
actual gene involved has remained very elusive. 
The Ct-'LlAC3, corresponds to the C'l'LA4 region on 
chromosome 2. This region contains three genes, the 
CTLA4 gene, CD28 and ICGS, whose products are 
lllvolved in the activation and control ot' the 'l'-Cells. 
CTLA4 and CD28 cellular membrane proteins compete 
for the Antigen Presenting Cell (APC) membrane 
protein, CD80/86. 
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If the latter product is missing, the 
T-cell undergoes apoptosis, whilst 
its interaction with CD28 induces 
T-cell proliferation and 
differentiation and its interaction 
with CTLA4, produces T-cell 
growth arrest. Thus, it was 
postulated that changes in the 
molecular structure of either of these 
two proteins could result in over-
stimulation of the T-cell with the 
resultant intestinal damage typical 
of coeliac disease. In actual fact, 
single nucleotide polymorphisms 
(SNPs) within this group have been 
associated with the condition whilst 
in others, including the local coeliac 
popUlation the same SNPs have 
been found to be protective. 
CELIAC4 locus is located on 
chromosome 19p13.1. Studies on 
the CELIAC4 locus revealed a 
significant and replicable 
association to a common variant 
located in intron 28 of the gene 
myosin IXB (MY09B). A defect in 
MY09B may be a factor involved 
in the early mucosal events 
preceding the inflammatory 
response. A genetic variant in the 
3-prime part of MY09B may 
interrupt the tight junction gate, 
consequently the immunogenic 
gluten peptides can enter the deeper 
mucosal layer more easily. 
In addition to the above, a number 
of genes have been associated with 
CD, in most cases following the 
genome-wide association study. 
Locally studies have been 
undertaken utilising a genome-wide 
linkage analysis approach on large 
families with multiple affected 
members. Though this work is still 
in its infancy, a novel mutation on 
the gene enl,;uuing the CD44 anu 
another mutation for the gene 
encoding the CD59 cell surface 
proteins were identified. 
As a conclusion, it appears that 
the genetic predisposition to CD 
depends on a single gene with a 
large etiect (HLA-D~2/DQ8), with 
a large group of other genes 
affecting the various aspects of 
innate and adaptive immunity and 
intestinal permeability. @ 
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Figurel. Interaction between the APC, T-cell, CD28, and CTLA-4. 
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